X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

By Michelle Drozd  |    March 27, 2017
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines...   Read More

Guest Post: The importance of a modern FDA in drug discovery

By Guest Contributor  |    March 22, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

3 things to know about 2016 drug approvals

By Andrew Powaleny  |    January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...   Read More

How modernizing FDA regulations can benefit patients, providers and payers

By Andrew Powaleny  |    September 1, 2016
Yesterday, the U.S. Food and Drug Administration (FDA) announced a two-day hearing slated for November 9 and 10, seeking public input as the agency works to review and potentially revise its policies...   Read More

Improving FDA’s combination product review process could increase epinephrine auto-injector competition

By Stephen J. Ubl  |    August 30, 2016
Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...   Read More

PhRMA & BIO release joint principles on communications with health care professionals and payers

By Jeff Francer  |    July 27, 2016
This blog post is authored by Jeffrey Francer (PhRMA) and Deborah Shelton (BIO). We are in an era of data-driven medicine. Patients, caregivers, health care professionals and insurers want more...   Read More

Video: How can biomarkers and surrogate endpoints enhance R&D of medicines?

By Andrew Powaleny  |    July 14, 2016
In the age of personalized medicine, biomarkers are emerging as important tools in drug development. A biomarker is a measure or physical sign that can be used to determine how the body is...   Read More

Advancing the science of hope

By Andrew Powaleny  |    June 13, 2016
Developing new medicines is a challenging undertaking, and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines, particularly...   Read More

Why incorporating patients’ perspectives matters

By Andrew Powaleny  |    June 10, 2016
America’s biopharmaceutical research companies have long been dedicated to researching and developing new medicines that enable patients to live longer, healthier lives. Patients’ voices are becoming...   Read More

The Science of Hope: Understanding biomarkers

By Andrew Powaleny  |    May 18, 2016
In the age of personalized medicine, biomarkers (short for “biological markers”) are emerging as important tools in drug development. A biomarker is a measure or physical sign that can be used to...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."